Relatively New Novel Oral Anticoagulants (NOACs) Slated To Boost Global Venous Thromboembolism Drugs Market

The report titled “PharmaPoint: Venous Thromboembolism - Global Drug Forecast And Market Analysis To 2025” provides a detailed overview the market for venous thromboembolism (VTE) drugs, including projections for its growth from 2015 to 2025.

The introductory part of the report presents a description of venous thromboembolism, covering aspects such as etiology, pathophysiology, symptoms, diagnosis, and treatment. VTE, which is a blood clot (thrombus) in the deep vein, results primarily in two life-threatening conditions: deep vein thrombosis (DVT) and pulmonary embolism (PE). VTE can occur and re-occur in both non-hospitalized and hospitalized individuals and can result in chronic complications, namely post-thrombotic syndrome (PTS) or chronic thromboembolic pulmonary hypertension (CTEPH). Though most commonly seen in adults and in the elderly, VTE can happen to people in any age group. Young patients afflicted by the malady usually have strong influencing factors, namely leg fractures, multiple trauma, or indwelling central vein lines.
Moving on, the report presents a list of growth drivers in the global VTE drug market. It points out that the relatively new drug called novel oral anticoagulants (NOACs) will be a major factor pushing the growth of the VTE market. NOACs, namely Xarelto, Pradaxa, Savaysa, and Eliquis present doctors with different treatment options, depending upon the patient’s condition. The report makes a comparative analysis of the drugs in terms of sales. It also details other forms of drugs such as arixtra (fondaparinux), heparins, and anti-platelets such as aspirin (widely genericized).

For Sample Copy, click here: http://www.marketresearchreports.biz/sample/sample/855951

The report delves into the clinical practices and trends in countries such as France, Italy, the U.S., Germany, Spain, Japan, and the U.K., vis-à-vis VTE. It discusses various unmet needs and opportunities in the market. These include optimal therapy for cancer patients, inadequate prophylaxis in acutely ill patients, best therapy for patients with moderate and severe renal failure, complicated dose adjustments with new oral anticoagulants, etc. The research study also outlines the scope for drug development in the VTE market.

Owing to extensive research and development, many drugs are already being developed and are slated to hit the market sooner or later. The report provides a peek into their clinical trial mapping and the countries that are developing them. It lists betrixaban (betrixaban) and xarelto (rivaroxaban) as the two of the most promising up and coming drugs. Further, the market study talks about other drugs in the pipeline, including anticoagulants, which are at a very early stage of development, and NOACs, which are in the most advanced stage of clinical trials.

Some of the big-ticket companies operating in the industry listed in the report are Boehringer Ingelheim, Janssen (Johnson & Johnson), Bayer, Bristol-Myers Squibb, Daiichi-Sankyo, and Pzifer.

MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

State Tower
90 State Street, Suite 700
Albany, NY 12207
United States
Tel: +1-518-621-2074
Website: http://www.marketresearchreports.biz/
Email: sales@marketresearchreports.biz

This release was published on openPR.